Skip to content
Briacell HTML Sitemap
Posts
- BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
- BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth LifeScience a Corporate Advisor
- BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
- BioNap Consulting's Jason Napodano Issues an Update on BriaCell Therapeutics Corp.
- Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com
- BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
- BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June
- BriaCell Appoints Jamieson Bondarenko to its Board of Directors
- BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences
- BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
- BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview
- BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study
- BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
- BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™
- BriaCell Completes Manufacturing of New Batch of BriaVax™
- BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™
- BriaCell Presenting at Upcoming Cancer Conference
- BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer
- BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
- BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease
- BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
- BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals
- BriaCell to Attend 20th Annual BIO CEO & Investor Conference
- BriaCell Therapeutics Corp. Announces Shares for Debt Issuance
- BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®
- BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020
- BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
- BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer
- BriaCell Announces Additional Capital Support by the CEO
- BriaCell Therapeutics Announces Hiring of CFO Gadi Levin; AGM Results
- BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
- BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance
- BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
- BriaCell Provides Clinical Development Update on BriaVax™
- BriaCell Provides A Corporate Update
- BriaCell Provides Research Update
- BriaCell To Present at Precision Breast Cancer Conference
- BriaCell Therapeutics Corp.’s CEO Talks Personalized Breast Cancer Treatment Technology with Uptick Newswire’s Stock Day Podcast
- BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
- BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation
- BriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million
- BriaCell Adds Third Clinical Site – Led by Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial in Advanced Breast Cancer
- BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax™
- BriaCell Appoints Top Social Media Marketing Analyst
- BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
- BriaCell Announces Repricing of Warrants
- BriaCell to Present at the 3rd Annual Biologics World Nordic 2020
- BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment with Leading U.S. Biotech Funds
- BriaCell Announces Investor and Media Outreach Programs
- BriaCell Announces Senior Management Change
- BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
- UPDATED - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
- BriaCell Announces Warrant Incentive Program
- BriaCell to Present Encouraging Clinical Data at AACR 2018
- Dr. Lacher’s interview with GenomeWeb - Dec 2016
- Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com
- BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
- BriaCell Included in the List of Key Players in Immuno-Oncology - Genome Web Interviews BriaCell’s Head of R&D -
- BriaCell Provides Highlights of Scientific and Clinical Findings at AACR
- BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
- BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting
- FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to their Immunotherapy in Patients with Advanced Breast Cancer
- BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
- BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax™ in Advanced Breast Cancer
- Expanding Breast Cancer Treatment Options: A Q&A with BriaCell on their Cancer Immunotherapy and their Pipeline
- BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic
- BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- BriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial
- BriaCell Provides Clinical Update
- BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)
- BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
- BriaCell Announces C$500,000 Equity Investment by BriaCell Director
- BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
- BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance
- Note from BriaCell Management – October is Breast Cancer Awareness Month
- Hired Dr. M. Lacher –Head of R&D -an expert in immuno-oncology & diagnostics
- BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
- BriaCell begins trading on the OTCQB (BCTXF)
- BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
- BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion
- Signed Definitive Agreement of Manufacturing of BriaVax at cGMP Facility- UC, Davis Health Center
- Hired seasoned biotech veteran Dr. Joseph Wagner as President and Chief Executive Officer
- BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement
- BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
- BriaCell Therapeutics Corp. completes its Initial Public Offering (IPO), & raises $US2.0M, trades at TSX Venture (BCT.V)
- Incorporated as a private Delaware company
- BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
- BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
- Dr. Bill Williams Guest Appearance at “CEO Money” Radio Show
- BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
- BriaCell’s Lead Product Candidate’s Novel Mechanism of Action Published in a Reputable Immunology Journal
- BriaCell Announces Collaboration with the National Cancer Institute
- BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
- BRIACELL THERAPEUTICS CORP. CLOSES DEBT FINANCING
- BriaCell Announces $350,000 Equity Investment by Board of Directors
- Bill Williams M.D. from BriaCell on CEO Money
- BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
- BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
- BriaCell Appoints Richard J. Berman to Board of Directors
- BriaCell Announces Closing of Warrant Incentive Program
- BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
- BriaCell Files Coronavirus Immunotherapy Patent
- BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax™ in Patients with Advanced Breast Cancer
- BriaCell Appoints Martin Schmieg to Board of Directors
- BriaCell Files a Patent Application to Protect Additional Cancer Vaccines with Genetic Features Thought to Promote Strong Anti-Tumor Activity
- BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases
- BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
- BriaCell Publishes Clinical Findings in 2018 American Society of Clinical Oncology (ASCO) Meeting
- BriaCell Closes CEO Equity Investment
- BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
- BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
- BriaCell To Attend Biotech Showcase™ 2018
- BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
- BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients
- BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
- BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
- BriaCell Presents Clinical Data at 2021 Keystone Symposium
- Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, Discusses Recent News and Progress in an Exclusive New Audio Interview with SmallCapVoice.com
- BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
- BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
- BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel
- BriaCell Files Patent Application for Novel Therapeutics for Cancer
- ASCO 2018: Interview with Dr. Saveri Bhattacharya on the ongoing Ph I/IIa clinical trial with BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer
- BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
- Initial Research Report (by RB Milestone Group) - BriaCell Therapeutics Corp. June 21, 2018
- BriaCell Announces Proposed Investment by Leading US Biotech Fund - Company Plans to Seek NASDAQ Uplisting –
- Consolidated Financial Statements For the Years Ended July 31, 2016 and 2015
- BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax™ Phase I/IIa Clinical Trial
- BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
- BriaCell Announces Private Placement of up to $600,000
- BriaCell Announces Non-Brokered Private Placement
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
- BriaCell to Hold Conference Call on Key Clinical Findings; Activities
- BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
- BriaCell Completes Previously Announced Investment with Leading U.S. Biotech Fund and Non-Brokered Private Placement
- Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
- BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
- BRIACELL ADDS U.S. BIOTECH VETERAN TO ITS BOARD OF DIRECTORS
- BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic
- The Wall Street Analyzer Interview with Dr. Williams - 2017
- BriaCell Therapeutics Corp. Announces Share Consolidation
- BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer
- BriaCell Therapeutics Corp. to Clarify Record Date
- BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing
- BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
- BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting
- Recording of The Webinar: BriaCell Therapeutics Corporate Update - June 28, 2018
- BriaCell Welcomes BioPharma Industry Experts to its Board of Directors
- BriaCell Completes Share Consolidation
- BriaCell Announces Closing of US$25 Million Public Offering
- BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
- BriaCell Therapeutics Corp. to File Amendment to Management Information Circular
- BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
- BriaCell Announces Closing of Non-Brokered Private Placement of $568,444
- BriaCell Launches Its Scientific Advisory Board
- BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
- BriaCell Announces Voting Results of the Special Meeting of Shareholders
- BriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer
- BriaCell Provides Update on Remarkable Responder
- BriaCell Announces Non-Brokered Private Placement
- BriaCell Appoints the Lead Principal Investigator and First Clinical Site for its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
- BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting
- BriaCell Closes Oversubscribed Non-Brokered Private Placement
Pages
Skip to content